Drug intelligence / Profile preview

FIT-001

Development stage: Phase 1
Lead developer: Guangzhou FineImmune Biotechnology
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

FIT-001 is an individualized T cell receptor engineered T cell (TCR-T) therapy developed by Guangzhou FineImmune Biotechnology Co., LTD. It is designed to treat advanced solid tumors by infusing tumor-specific TCR-T cells intravenously. The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells, with a secondary purpose to preliminarily show their effect in the treatment of advanced solid tumors.

Other names: tumor-specific TCR-T cells

Targets

FTase (Protein Farnesyltransferase)HRAS (H-Ras protein)

Beyond the preview

Go deeper on FIT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIT-001.

Explore the full profile